Heyholder
‹ Activism Filings

DaehanPharmaceutical Q3 profit from the main business KRW 8.2 billion, down 23.0% from a year earlier

DaehanPharmaceutical· Periodic Report

AI summary · Not investment advice

Daehan Pharm sold KRW 57.0 billion in Q3 and earned KRW 8.2 billion from its main business, down 23.0% from a year earlier and up 1.4% from the prior quarter.

Operating profit · 3 months

KRW 8.2 billion

Key facts

Revenue (3 months)
KRW 57.0 billion
Net income (3 months)
KRW 5.6 billion
Period
Q3 (cumulative 2026.01.01 ~ 2026.09.30)
Revenue (prior-year 3 months)
KRW 56.2 billion
Revenue (year to date)
KRW 166.3 billion
Operating profit (prior-year 3 months)
KRW 10.6 billion
Operating profit (year to date)
KRW 24.1 billion
Net income (prior-year 3 months)
KRW 8.7 billion
Net income (year to date)
KRW 19.4 billion

Commentary

AI commentary · Not investment advice

What happened

Daehan Pharm reported its third-quarter 2026 results (July to September) on a standalone basis. Sales for the quarter were KRW 57.03 billion. That is 1.5% higher than the same 3 months a year earlier (KRW 56.17 billion) and 0.7% higher than the previous quarter.

In the company's terms

Operating profit (profit from the core business) for the quarter was KRW 8.19 billion. It fell 23.0% from the same 3 months a year earlier (KRW 10.64 billion) and rose 1.4% from the previous quarter. Net income (the final profit after taxes and other costs) was KRW 5.65 billion. It fell 35.2% from a year earlier (KRW 8.72 billion) and fell 16.3% from the previous quarter.

What changes for shareholders

For the year to date (January 1 to September 30), sales were KRW 166.35 billion. Operating profit was KRW 24.13 billion and net income was KRW 19.38 billion.

Comments

No comments yet

Comments from shareholders will appear here.